EXPERIENCE OF USING BEDAQUILINE IN THE TREATMENT OF PULMONARY TUBERCULOSIS PATIENTS WITH MULTIPLE ANDEXTENSIVE DRUG RESISTANCE
https://doi.org/10.21292/2075-1230-2017-95-12-49-53
Abstract
The article presents the evaluation of safety and efficiency of chemotherapy regimens including the new anti-tuberculosis agent of bedaquiline in 21 pulmonary tuberculosis patients with multiple and extensive drug resistance who were treated in Stavropol Regional Clinical TB Dispensary from 2014 to 2017. It was found out that regimens with bedaquiline were satisfactory tolerated, and the attempt to identify the agent causing adverse events within a multi-component chemotherapy regimen failed. The majority of adverse events were reversible, but they required temporary cancellation of chemotherapy in 5 patients with the consequent continuation of treatment with this regimen after adverse events were managed. The evaluation of treatment efficiency with 6-month treatment with bedaquiline showed sputum conversion in 94.4% of cases and healing of cavities in 72.2%.
About the Authors
N. M. Konovаlovа
Stavropol Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Natalia M. Konovalova – Phthisiologists of the Highest Degree.
56, Dostoevsky St., Stavropol, 355019
V. S. Odinets
Stavropol Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Vasily S. Odinets – Candidate of Medical Sciences, Chief Doctor.
56, Dostoevsky St., Stavropol, 355019
T. I. Vаsilenko
Stavropol Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Tatyana I. Vasilenko – Deputy Head Doctor for Medical Activities
56, Dostoevsky St., Stavropol, 355019
T. A. Zаdremаylovа
Stavropol Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Tatyana A. Zadremaylova – Deputy Head Doctor on Reporting and Statistics.
56, Dostoevsky St., Stavropol, 355019
References
1. Use guidelines for Sirturo®. Registration number: LP-002281. (Epub.) URL: http://www.ros-med.info/reestrls/ info.php?action=info&id=26223. (Accessed as of 20.04.2015).
2. Nechaeva O.B. Osnovnye pokazateli po tuberkulezu po Rossiyskoy Federatsii. [Main tuberculosis rates in the Russian Federation]. http://mednet.ru/images/stories/files/news/tb_za_2016.pdf
3. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. Moscow, Tver, OOO Izdatelstvo Triada Publ., 2014, 72 p.
4. Pym A.S., Diacon A.H., Tang S.J., Conradie F., Danilovits M., Chuchottaworn C., Vasilyeva I., Andries K., Bakare N., de Marez T., Haxaire-Theeuwes M., Lounis N., Meyvisch P., Van Baelen B., van Heeswijk R.P., Dannemann B. TMC207-C209 Study Group. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur. Respir. J., 2016, vol. 47, no. 2, pp. 564-574. doi: 10.1183/13993003.00724-2015.
Review
For citations:
Konovаlovа N.M., Odinets V.S., Vаsilenko T.I., Zаdremаylovа T.A. EXPERIENCE OF USING BEDAQUILINE IN THE TREATMENT OF PULMONARY TUBERCULOSIS PATIENTS WITH MULTIPLE ANDEXTENSIVE DRUG RESISTANCE. Tuberculosis and Lung Diseases. 2017;95(12):49-53. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-12-49-53
Views:
1599
Email this article 